Home
MRK
MRK News

Latest Merck & Company Inc. (new) (MRK) News on November 23, 2025

Merck (NYSE:MRK) Has Announced That It Will Be Increasing Its Dividend To $0.85

Simply Wall St.

a day ago

Merck (NYSE:MRK) Has Announced That It Will Be Increasing Its Dividend To $0.85

Looking For Yields: Merck, Altria, And Genuine Parts Are Consistent Moneymakers

Benzinga

a day ago

Looking For Yields: Merck, Altria, And Genuine Parts Are Consistent Moneymakers

Merck Recommends Rejection of Tutanota’s "Mini-Tender" Offer

Business Wire

a day ago

Merck Recommends Rejection of Tutanota’s "Mini-Tender" Offer

Mettler-Toledo, Agilent, Waters Corporation, Merck, and Regeneron Shares Skyrocket, What You Need To Know

StockStory

a day ago

Mettler-Toledo, Agilent, Waters Corporation, Merck, and Regeneron Shares Skyrocket, What You Need To Know

Stock Market Today: Dow Gains Nearly 500 Points After Whipsaw Action As Nvidia Finishes Lower (Live Coverage)

Investor's Business Daily

2 days ago

Stock Market Today: Dow Gains Nearly 500 Points After Whipsaw Action As Nvidia Finishes Lower (Live Coverage)

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), as Perioperative Treatment for Adults with Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

Business Wire

2 days ago

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), as Perioperative Treatment for Adults with Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

MT Newswires

2 days ago

Sector Update: Health Care Stocks Higher Late Afternoon

Medtronic (MDT)’s CEO “is One of the Finest People,” Says Jim Cramer

Insider Monkey

2 days ago

Medtronic (MDT)’s CEO “is One of the Finest People,” Says Jim Cramer

PFE's New & Acquired Drugs Drive Non-COVID Comeback as LOE Test Looms

Zacks

2 days ago

PFE's New & Acquired Drugs Drive Non-COVID Comeback as LOE Test Looms

The Zacks Analyst Blog Highlights Visa, Merck, Southern Company, Community Bancorp and Comstock

Zacks

2 days ago

The Zacks Analyst Blog Highlights Visa, Merck, Southern Company, Community Bancorp and Comstock

Top Analyst Reports for Visa, Merck & Southern Company

Zacks

3 days ago

Top Analyst Reports for Visa, Merck & Southern Company

MT Newswires

3 days ago

Sector Update: Health Care Stocks Softer Late Afternoon

MT Newswires

3 days ago

Sector Update: Health Care Stocks Lower Thursday Afternoon

Merck's $3 Billion AI Gamble: Inside the Bold Bet to Crack Parkinson's

GuruFocus.com

3 days ago

Merck's $3 Billion AI Gamble: Inside the Bold Bet to Crack Parkinson's

Merck KGaA eyes new Parkinson’s disease assets with $3bn Valo partnership

Pharmaceutical Technology

3 days ago

Merck KGaA eyes new Parkinson’s disease assets with $3bn Valo partnership

VIPC Signs MOU with AstraZeneca, Eli Lilly, Merck to Develop the Virginia Center for Advanced Pharmaceutical Manufacturing to Train Workforce of the Future

PR Newswire

3 days ago

VIPC Signs MOU with AstraZeneca, Eli Lilly, Merck to Develop the Virginia Center for Advanced Pharmaceutical Manufacturing to Train Workforce of the Future

MT Newswires

3 days ago

Merck Completes Negotiations for Pulmonary Arterial Hypertension Treatment With Canadian Body

Edgewise Therapeutics Appoints Commercial Biotech Executive Christopher Martin to its Board of Directors

PR Newswire

3 days ago

Edgewise Therapeutics Appoints Commercial Biotech Executive Christopher Martin to its Board of Directors

This Drugmaker Is Too Cheap to Ignore. Why Bristol Is a Buy.

Barrons.com

3 days ago

This Drugmaker Is Too Cheap to Ignore. Why Bristol Is a Buy.

Merck Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully complete negotiations for WINREVAIR® (sotatercept)

CNW Group

3 days ago

Merck Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully complete negotiations for WINREVAIR® (sotatercept)

Cidara Therapeutics Is Up Over 100%. Here's What Investors Need to Know.

Motley Fool

3 days ago

Cidara Therapeutics Is Up Over 100%. Here's What Investors Need to Know.

133-year-old big pharma company plans layoffs, files WARN notice

TheStreet

3 days ago

133-year-old big pharma company plans layoffs, files WARN notice

2 Healthcare Stocks Worth Your Attention and 1 We Ignore

StockStory

4 days ago

2 Healthcare Stocks Worth Your Attention and 1 We Ignore

Merck Stock Rise as New PAH Drug Winrevair Meets Goal in Another Study

Zacks

4 days ago

Merck Stock Rise as New PAH Drug Winrevair Meets Goal in Another Study

Metrorrhagia Market Analysis Report 2025-2035, Profiles of Pfizer, Sandoz, Bayer, Actavis Pharma, Noven Pharmaceuticals, Theramex, Pantarhei Bioscience, AbbVie, Neurocrine Biosciences, Merck

GlobeNewswire

4 days ago

Metrorrhagia Market Analysis Report 2025-2035, Profiles of Pfizer, Sandoz, Bayer, Actavis Pharma, Noven Pharmaceuticals, Theramex, Pantarhei Bioscience, AbbVie, Neurocrine Biosciences, Merck

Merck (MRK): Is There Still Value After the Recent Share Price Rally?

Simply Wall St.

4 days ago

Merck (MRK): Is There Still Value After the Recent Share Price Rally?

MT Newswires

4 days ago

Merck's Investigational Drug in Treatment-Naive Adults with HIV-1 Infection Shows Primary Efficacy

MT Newswires

4 days ago

Merck Says European Commission Approves Subcutaneous Version of Keytruda

SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK

GlobeNewswire

4 days ago

SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK

Merck Announces Positive Topline Results from the Pivotal Phase 3 Trial Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) in Treatment-Naïve Adults with HIV-1 Infection

Business Wire

4 days ago

Merck Announces Positive Topline Results from the Pivotal Phase 3 Trial Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) in Treatment-Naïve Adults with HIV-1 Infection

MT Newswires

4 days ago

Berenberg Adjusts Price Target on Merck & Co. to $95 From $90, Maintains Hold Rating

MT Newswires

4 days ago

Rothschild & Co Redburn Adjusts Price Target on Merck & Co. to $125 From $120, Maintains Buy Rating

Merck’s WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Phase 2 CADENCE Study in Adults With Combined Post- and Precapillary Pulmonary Hypertension (CpcPH) due to Heart Failure With Preserved Ejection Fraction (HFpEF)

Business Wire

5 days ago

Merck’s WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Phase 2 CADENCE Study in Adults With Combined Post- and Precapillary Pulmonary Hypertension (CpcPH) due to Heart Failure With Preserved Ejection Fraction (HFpEF)

Is Merck's Recent FDA Approval a Game Changer for Its Share Price?

Simply Wall St.

5 days ago

Is Merck's Recent FDA Approval a Game Changer for Its Share Price?

[Latest] Global NUT Midline Carcinoma Treatment Market Size/Share Worth USD 93.34 Billion by 2034 at a 15.26% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT)

GlobeNewswire

5 days ago

[Latest] Global NUT Midline Carcinoma Treatment Market Size/Share Worth USD 93.34 Billion by 2034 at a 15.26% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT)

MT Newswires

6 days ago

Sector Update: Health Care Stocks Softer Late Afternoon

Morningstar Research

6 days ago

Analyst Report: Merck & Co., Inc.

MRK to Buy Cidara for $9.2B: Focus on Buyout Spree Heading Into 2026

Zacks

6 days ago

MRK to Buy Cidara for $9.2B: Focus on Buyout Spree Heading Into 2026

MRK Up Nearly 10% in a Month: Should You Buy, Sell or Hold the Stock?

Zacks

6 days ago

MRK Up Nearly 10% in a Month: Should You Buy, Sell or Hold the Stock?

Solve Therapeutics Raises $120 Million to Develop Best-in-Class ADCs for Solid Tumors

Business Wire

6 days ago

Solve Therapeutics Raises $120 Million to Develop Best-in-Class ADCs for Solid Tumors

Investing.com

6 days ago

Cidara downgraded on Wall Street after Merck agrees to $9.2 billion buyout

MT Newswires

6 days ago

Jefferies Adjusts Price Target on Merck & Co. to $138 From $137, Maintains Buy Rating

Solve lines up $120M to push ADCs into further testing

BioPharma Dive

6 days ago

Solve lines up $120M to push ADCs into further testing

Financial Times

6 days ago

Goldman Sachs on brink of best M&A performance in 24 years

Cidara (CDTX) Climbs 105% on $9.2-Billion Merger with Merck

Insider Monkey

7 days ago

Cidara (CDTX) Climbs 105% on $9.2-Billion Merger with Merck

Cidara Therapeutics (CDTX) Skyrockets 105% on Merck $9.2-Billion Acquisition Bid

Insider Monkey

8 days ago

Cidara Therapeutics (CDTX) Skyrockets 105% on Merck $9.2-Billion Acquisition Bid

Companies Like Marks Electrical Group (LON:MRK) Are In A Position To Invest In Growth

Simply Wall St.

8 days ago

Companies Like Marks Electrical Group (LON:MRK) Are In A Position To Invest In Growth

Dow Drops For Second Day Amid Uncertainty Around December Rate Cut

MT Newswires

9 days ago

Dow Drops For Second Day Amid Uncertainty Around December Rate Cut

Merck Swoops In On Buyout Bonanza With A $9.2 Billion Cidara Therapeutics Deal

Investor's Business Daily

9 days ago

Merck Swoops In On Buyout Bonanza With A $9.2 Billion Cidara Therapeutics Deal

MT Newswires

9 days ago

Sector Update: Health Care Stocks Ease Late Afternoon

MT Newswires

9 days ago

US Equity Indexes Mixed Amid Technology Rebound

This Biotech's Stock Price More Than Doubled on Friday. Here's Why.

Investopedia

9 days ago

This Biotech's Stock Price More Than Doubled on Friday. Here's Why.

ACCESS Newswire

9 days ago

RedChip Companies Congratulates Former Client Cidara Therapeutics on Its $9.2 Billion Acquisition by Merck

Stocks to Watch Friday: Walmart, Cidara, Warner Bros.

The Wall Street Journal

9 days ago

Stocks to Watch Friday: Walmart, Cidara, Warner Bros.

Financial Times

9 days ago

Merck agrees $9.2bn deal for flu-prevention biotech Cidara

MT Newswires

9 days ago

Sector Update: Health Care Stocks Decline Premarket Friday

MT Newswires

9 days ago

Wall Street Weighs Tech Valuations, Fed Outlook as US Equity Futures Fall Pre-Bell

Merck to Acquire Cidara Therapeutics in $9.2 Billion Deal

MT Newswires

9 days ago

Merck to Acquire Cidara Therapeutics in $9.2 Billion Deal

Do You Believe in Merck & Co.’s (MRK) Upside Potential?

Insider Monkey

9 days ago

Do You Believe in Merck & Co.’s (MRK) Upside Potential?

This Biotech Stock Is Soaring 100%. Merck Is Buying It.

Barrons.com

9 days ago

This Biotech Stock Is Soaring 100%. Merck Is Buying It.

Pharma ETFs in Spotlight Following Robust Q3 Earnings Results

Zacks

9 days ago

Pharma ETFs in Spotlight Following Robust Q3 Earnings Results

Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls

The Fly

10 days ago

Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls

Merck to Participate in the Jefferies Global Healthcare Conference in London

Business Wire

10 days ago

Merck to Participate in the Jefferies Global Healthcare Conference in London

MT Newswires

10 days ago

Scotiabank Initiates Merck & Co. at Sector Outperform With $105 Price Target

Should You Forget Pfizer and Buy This Magnificent Drug Stock Instead?

Motley Fool

10 days ago

Should You Forget Pfizer and Buy This Magnificent Drug Stock Instead?

1 Incredible Reason to Buy LLY's Stock in November

Motley Fool

10 days ago

1 Incredible Reason to Buy LLY's Stock in November

MT Newswires

11 days ago

Merck & Co. Insider Sold Shares Worth $616,395, According to a Recent SEC Filing

Merck (MRK) Is Up 8.5% After Promising Oral PCSK9 Cholesterol Drug Trial Results – Has The Bull Case Changed?

Simply Wall St.

11 days ago

Merck (MRK) Is Up 8.5% After Promising Oral PCSK9 Cholesterol Drug Trial Results – Has The Bull Case Changed?

2 Strong Healthcare Stock Picks for Value Investors

Motley Fool

11 days ago

2 Strong Healthcare Stock Picks for Value Investors

2 Stocks Down 13% and 34% to Buy Right Now

Motley Fool

11 days ago

2 Stocks Down 13% and 34% to Buy Right Now

Stocks Gain Pre-Bell Ahead of Looming House Vote to End Government Shutdown

MT Newswires

11 days ago

Stocks Gain Pre-Bell Ahead of Looming House Vote to End Government Shutdown

Lantheus, Enovis, Evolent Health, Repligen, and Corcept Shares Are Soaring, What You Need To Know

StockStory

12 days ago

Lantheus, Enovis, Evolent Health, Repligen, and Corcept Shares Are Soaring, What You Need To Know

Merck, Elanco, Myriad Genetics, Neogen, and Cigna Shares Are Soaring, What You Need To Know

StockStory

12 days ago

Merck, Elanco, Myriad Genetics, Neogen, and Cigna Shares Are Soaring, What You Need To Know

Gilead Sciences, Moderna, Artivion, Tenet Healthcare, and Charles River Laboratories Stocks Trade Up, What You Need To Know

StockStory

12 days ago

Gilead Sciences, Moderna, Artivion, Tenet Healthcare, and Charles River Laboratories Stocks Trade Up, What You Need To Know

Viatris, Oscar Health, BioMarin Pharmaceutical, QuidelOrtho, and Bausch + Lomb Stocks Trade Up, What You Need To Know

StockStory

12 days ago

Viatris, Oscar Health, BioMarin Pharmaceutical, QuidelOrtho, and Bausch + Lomb Stocks Trade Up, What You Need To Know

Elevance Health, Labcorp, Privia Health, Fortrea, and Amgen Shares Are Soaring, What You Need To Know

StockStory

12 days ago

Elevance Health, Labcorp, Privia Health, Fortrea, and Amgen Shares Are Soaring, What You Need To Know

Bio-Techne, Tandem Diabetes, Align Technology, DexCom, and Teleflex Shares Skyrocket, What You Need To Know

StockStory

12 days ago

Bio-Techne, Tandem Diabetes, Align Technology, DexCom, and Teleflex Shares Skyrocket, What You Need To Know

Merck’s Heart Pill Slashes Cholesterol Levels in Test Patients

Barrons.com

13 days ago

Merck’s Heart Pill Slashes Cholesterol Levels in Test Patients

Top 3 Dividend Stocks To Enhance Your Portfolio

Simply Wall St.

13 days ago

Top 3 Dividend Stocks To Enhance Your Portfolio

Will Keytruda Aid MRK's Growth in 2026 After a Subdued Q3?

Zacks

13 days ago

Will Keytruda Aid MRK's Growth in 2026 After a Subdued Q3?

AIM ImmunoTech Details New UPMC Abstract on Completed Clinical Trial Involving Ampligen’s Synergistic Potential in the Treatment of Advanced Recurrent Ovarian Cancer

GlobeNewswire

13 days ago

AIM ImmunoTech Details New UPMC Abstract on Completed Clinical Trial Involving Ampligen’s Synergistic Potential in the Treatment of Advanced Recurrent Ovarian Cancer

Bristol Myers Gains 7.2% in a Month: Buy, Sell or Hold the Stock?

Zacks

13 days ago

Bristol Myers Gains 7.2% in a Month: Buy, Sell or Hold the Stock?

MT Newswires

13 days ago

Leerink Partners Adjusts Price Target on Merck to $114 From $107

Factbox-Major deals involving U.S. drugmakers and biotechs over the past decade

Reuters

13 days ago

Factbox-Major deals involving U.S. drugmakers and biotechs over the past decade

MT Newswires

13 days ago

Merck's Phase 3 Trial of Enlicitide Decanoate in Heterozygous Familial Hypercholesterolemia Achieves Primary Endpoint

Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with Heterozygous Familial Hypercholesterolemia (HeFH) in Phase 3 CORALreef HeFH Trial

Business Wire

14 days ago

Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with Heterozygous Familial Hypercholesterolemia (HeFH) in Phase 3 CORALreef HeFH Trial

More Drugs to Fight High Cholesterol Are Emerging

The Wall Street Journal

15 days ago

More Drugs to Fight High Cholesterol Are Emerging

Merck Takes On Amgen, Regeneron, Lowering Stubbornly High Cholesterol By 60%

Investor's Business Daily

15 days ago

Merck Takes On Amgen, Regeneron, Lowering Stubbornly High Cholesterol By 60%

Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial

Business Wire

15 days ago

Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial

Morgan Stanley Raises Merck (MRK) Price Target to $100, Maintains Equal Weight Rating

Insider Monkey

15 days ago

Morgan Stanley Raises Merck (MRK) Price Target to $100, Maintains Equal Weight Rating

Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock

Zacks

16 days ago

Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock

3 Dirt Cheap Stocks to Buy With $1,000 Right Now

Motley Fool

16 days ago

3 Dirt Cheap Stocks to Buy With $1,000 Right Now

Codexis Inc (CDXS) Q3 2025 Earnings Call Highlights: Strategic Shifts and New Partnerships ...

GuruFocus.com

16 days ago

Codexis Inc (CDXS) Q3 2025 Earnings Call Highlights: Strategic Shifts and New Partnerships ...

2 Safe-and-Steady Stocks Worth Your Attention and 1 We Turn Down

StockStory

16 days ago

2 Safe-and-Steady Stocks Worth Your Attention and 1 We Turn Down

Endometrial Cancer Market Poised for Expansion Throughout Forecast Period (2025-2034) Amid Increasing Adoption of Immunotherapies | DelveInsight

PR Newswire

17 days ago

Endometrial Cancer Market Poised for Expansion Throughout Forecast Period (2025-2034) Amid Increasing Adoption of Immunotherapies | DelveInsight

Codexis Reports Third Quarter 2025 Financial Results

GlobeNewswire

17 days ago

Codexis Reports Third Quarter 2025 Financial Results

Moderna Q3 Earnings Beat, Stock Up on Revised '25 Spending Plans

Zacks

17 days ago

Moderna Q3 Earnings Beat, Stock Up on Revised '25 Spending Plans

AZN Q3 Earnings Top Estimates, Sales Rise As Most Key Drugs Outperform

Zacks

17 days ago

AZN Q3 Earnings Top Estimates, Sales Rise As Most Key Drugs Outperform

PLANET HOME ANNOUNCES $1 MILLION TOUGH TECH PRIZE AT INAUGURAL GALA DURING TOUGH TECH WEEK

PR Newswire

17 days ago

PLANET HOME ANNOUNCES $1 MILLION TOUGH TECH PRIZE AT INAUGURAL GALA DURING TOUGH TECH WEEK

AstraZeneca CEO bullish on record revenue numbers and US growth

Yahoo Finance Video

17 days ago

AstraZeneca CEO bullish on record revenue numbers and US growth

Share on Social Networks: